EFFECTIVENESS AND COST-EFFECTIVENESS OF TRIPLE THERAPY WITH TELAPREVIR AND BOCEPREVIR FOR CHRONIC HEPATITIS C: A DECISION ANALYSIS FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM

被引：0
|
作者：
Borba, H. H. [1 ]
Rochau, U. [2 ]
Wiens, A. [1 ]
Sroczynski, G. [2 ]
Siebert, U. [3 ]
Pontarolo, R. [1 ]
机构：
[1] Univ Fed Parana, Curitiba, Parana, Brazil
[2] UMIT Univ Hlth Sci Med Informat & Technol, Inst Publ Hlth Med Decis Making & HTA, Dept Publ Hlth Hlth Serv Res & HTA, Hall In Tirol, Austria
[3] UMIT Univ Hlth Sci Med Informat & Technol, Dept Publ Hlth Hlth Serv Res & Hlth Technol Asses, Hall In Tirol, Austria
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.2627
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PGI9
引用
收藏
页码：A883 / A883
页数：1
相关论文
共 50 条
  • [1] Effectiveness and Cost-Effectiveness of Triple Therapy With Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis From the Brazilian Public Health System Perspective
    Borba, Helena H. L.
    Rochau, Ursula
    Wiens, Astrid
    Sroczynski, Gaby
    Siebert, Uwe
    Ferreira, Vinicius L.
    Minowa, Eimy
    Pontarolo, Roberto
    VALUE IN HEALTH REGIONAL ISSUES, 2019, 20 : 95 - 102
  • [2] A COST-EFFECTIVENESS ANALYSIS OF TELAPREVIR VERSUS BOCEPREVIR IN THE TREATMENT OF HEPATITIS C: A GREEK NATIONAL HEALTH SYSTEM PERSPECTIVE
    Yfantopoulos, J.
    Paparouni, K.
    D'Angelo, E. R.
    VALUE IN HEALTH, 2012, 15 (07) : A394 - A394
  • [3] Effectiveness of telaprevir/boceprevir-based triple therapy for chronic hepatitis c
    Garcia-Queiruga, Marta
    Purificacion, Cid
    Laura Maria, Martinez-Lopez
    Marta, Leston
    Luis, Margusino
    Isabel, Martin
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2015, 37 (01) : 280 - 281
  • [4] Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Enea, Marco
    Bruno, Raffaele
    Bronte, Fabrizio
    Capursi, Vincenza
    Cicchetti, Americo
    Colombo, Giorgio L.
    Di Marco, Vito
    Gasbarrini, Antonio
    Craxi, Antonio
    HEPATOLOGY, 2012, 56 (03) : 850 - 860
  • [5] Cost-effectiveness of Telaprevir Combination Therapy for Chronic Hepatitis C
    Brogan, Anita J.
    Talbird, Sandra E.
    Thompson, James R.
    Miller, Jeffrey D.
    Rubin, Jaime
    Deniz, Baris
    PLOS ONE, 2014, 9 (03):
  • [6] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [7] The cost-effectiveness of boceprevir for hepatitis C
    Neoh, Chin Fen
    Kong, David C. M.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (03) : 319 - 334
  • [8] THE COST-EFFECTIVENESS OF TELAPREVIR TRIPLE THERAPY IN TREATMENT-EXPERIENCED CHRONIC HEPATITIS C PATIENTS IN TURKEY
    Ozdemir, O.
    VALUE IN HEALTH, 2014, 17 (07) : A670 - A670
  • [9] COST-EFFECTIVENESS OF SIMEPREVIR VS. TELAPREVIR FOR THE TRIPLE THERAPY OF HEPATITIS C IN KAZAKHSTAN
    Bektur, C.
    Nurgozhin, T.
    Abdukhakimova, D.
    VALUE IN HEALTH, 2015, 18 (07) : A627 - A627
  • [10] Cost-effectiveness and safety of telaprevir and boceprevir for chronic hepatitis C in real-world clinical practice
    Gimenez-Manzorro, Alvaro
    Garcia-Gonzalez, Xandra
    Guadalupe Rodriguez-Gonzalez, Carmen
    Ochoa-Palominos, Alejandra
    Sanjurjo-Saez, Maria
    Clemente-Ricote, Gerardo
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2015, 38 (10): : 575 - 582
12345